Expression analysis of human CEACAM5 on HEK293/Human CEACAM5 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human CEACAM5 Stable Cell Line or negative control cell using PE-labeled anti-human CEACAM5 antibody.
Anti-CEACAM-5 (labetuzumab) Antibody, Human IgG1 captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Biotinylated Human CEACAM-5, His,Avitag (Cat. No. CE5-H82E0) with an affinity constant of 12.1 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Tusamitamab Ravtansine | SAR-408701; IBI-126 | Phase 3 Clinical | Immunogen Inc | Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Metastatic breast cancer; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
SGM-101 | SGM-101 | Phase 3 Clinical | Surgimab Sas | Intestinal Neoplasms; Gastrointestinal Diseases; Rectal Neoplasms; Brain Diseases; Colonic Neoplasms; Pancreatic Neoplasms; Brain Neoplasms; Colorectal Neoplasms; Colonic Diseases; Brain metastases; Intestinal Diseases; Gastrointestinal Neoplasms | Details |
Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) | CVAC-301; CV-301 | Phase 2 Clinical | Therion Biologics | Intestinal Neoplasms; Solid tumours; Cystadenocarcinoma; Ovarian Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Melanoma; Neoplasm Metastasis; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
NEO-201 | NEO-201 | Phase 2 Clinical | Precision Biologics Inc, National Cancer Institute | Squamous Cell Carcinoma of Head and Neck; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Anti-CEA CAR T cell therapy (Shanghai GeneChem) | Phase 2 Clinical | Shanghai Genechem Co Ltd | Liver Neoplasms; Colorectal Neoplasms | Details | |
LM-24C5 | LM-24C5 | Phase 2 Clinical | LaNova Medicines Ltd | Solid tumours; Neoplasms | Details |
M-9140 | M-9140; M9140 | Phase 2 Clinical | Merck KGaA, Darmstadt, Germany | Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
MFE-23-CD3z T cell therapy (Cancer Research Technology) | Phase 1 Clinical | Cancer Research Technology | Neoplasms | Details | |
125-Iodine-labeled MFE-23 | Phase 1 Clinical | Cancer Research UK | Neoplasms | Details | |
anti-CEA CAR-T cell therapy (Sorrento/TNK therapeutics/Roger Williams Medical Center) | Phase 1 Clinical | Beth Israel Deaconess Medical Center | Solid tumours; Liver Neoplasms; Pancreatic Neoplasms; Neoplasms; Neoplasm Metastasis; Adenocarcinoma | Details | |
SGN-CEACAM5C | PF-08046050; SAR445953; SGN-CEACAM5C; SAR-445953 | Phase 1 Clinical | Seagen Inc, Sanofi | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
EBC-129 | EBC-129; EBC129 | Phase 1 Clinical | Experimental Drug Development Centre | Solid tumours | Details |
BGB-B167 | BGB-B167 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours | Details |
GB-5012 | GB-5012 | Clinical | Shanghai Genbase Biotechnology Co Ltd | Colonic Neoplasms | Details |
This web search service is supported by Google Inc.